{
    "relation": [
        [
            "",
            "TMC278",
            "Efavirenz"
        ],
        [
            "Description",
            "25 milligram (mg) tablet once daily for 96 weeks.",
            "600 mg once daily for 96 weeks."
        ]
    ],
    "pageTitle": "TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine. - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00540449?sect=X0125&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042982745.46/warc/CC-MAIN-20150728002302-00325-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 873541231,
    "recordOffset": 873520896,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details One hundred and twelve sites in 21 countries randomized participants. In total, 694 participants were randomized: four participants did not start treatment and 690 participants started treatment (346 in the TMC278 group and 344 in the efavirenz [control ] group). Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: TMC278 Drug: Efavirenz Interventions: HIV Infections HIV-1 Human Immunodeficiency Virus Type 1 Conditions: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 TMC278 \u00a0 \u00a0 Efavirenz \u00a0 STARTED \u00a0 \u00a0 346 \u00a0 \u00a0 344 \u00a0 COMPLETED \u00a0 \u00a0 262 \u00a0 \u00a0 266 \u00a0 NOT COMPLETED \u00a0 \u00a0 84 \u00a0 \u00a0 78 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 12 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 32 \u00a0 Sponsor's Decision \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Subject Ineligible To Continue The Trial \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}